Literature DB >> 30299299

Pharmacokinetics of Sildenafil in Patients with a Left Ventricular Assist Device: A Word of Caution.

Leah A Sabato1, Daniel C Johnson1, Nicholas Haglund2, Mary Keebler1, Zachary L Cox3.   

Abstract

We compared maximal plasma concentrations (Cmax) of sildenafil and metabolite n-desmethyl sildenafil in 12 inpatients with left ventricular assist devices (LVADs) on sildenafil (60 mg/day) to the reference range. Sildenafil Cmax (156.8 ± 124.5 ng/ml) was elevated in 66% of patients, with a two to fivefold increase over the upper limit of the reference range in 25% of patients. Metabolite Cmax (133.3 ± 102.0 ng/ml) was elevated in 75% of patients, with a three to sevenfold increase over the upper limit of the reference range in 40% of patients. Patients with heart failure and LVADs are at increased risk of concentrated-related sildenafil adverse events.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30299299      PMCID: PMC6447486          DOI: 10.1097/MAT.0000000000000886

Source DB:  PubMed          Journal:  ASAIO J        ISSN: 1058-2916            Impact factor:   2.872


  5 in total

Review 1.  Drug interactions with phosphodiesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertension.

Authors:  Bryan G Schwartz; Robert A Kloner
Journal:  Circulation       Date:  2010-07-06       Impact factor: 29.690

Review 2.  ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association.

Authors:  M D Cheitlin; A M Hutter; R G Brindis; P Ganz; S Kaul; R O Russell; R M Zusman
Journal:  J Am Coll Cardiol       Date:  1999-01       Impact factor: 24.094

3.  Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.

Authors:  Margaret M Redfield; Horng H Chen; Barry A Borlaug; Marc J Semigran; Kerry L Lee; Gregory Lewis; Martin M LeWinter; Jean L Rouleau; David A Bull; Douglas L Mann; Anita Deswal; Lynne W Stevenson; Michael M Givertz; Elizabeth O Ofili; Christopher M O'Connor; G Michael Felker; Steven R Goldsmith; Bradley A Bart; Steven E McNulty; Jenny C Ibarra; Grace Lin; Jae K Oh; Manesh R Patel; Raymond J Kim; Russell P Tracy; Eric J Velazquez; Kevin J Anstrom; Adrian F Hernandez; Alice M Mascette; Eugene Braunwald
Journal:  JAMA       Date:  2013-03-27       Impact factor: 56.272

4.  Pharmacokinetics and safety of ambrisentan in combination with sildenafil in healthy volunteers.

Authors:  Rebecca Spence; Arun Mandagere; Christopher Dufton; Jürgen Venitz
Journal:  J Clin Pharmacol       Date:  2008-10-01       Impact factor: 3.126

5.  CYP3A4 genotype is associated with sildenafil concentrations in patients with heart failure with preserved ejection fraction.

Authors:  S de Denus; J L Rouleau; D L Mann; G S Huggins; N L Pereira; S H Shah; T P Cappola; R Fouodjio; I Mongrain; M-P Dubé
Journal:  Pharmacogenomics J       Date:  2017-04-25       Impact factor: 3.550

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.